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ABSTRACT 
Background: Few studies have examined the associations of serum magnesium (Mg) 
concentrations with total and cause-specific mortality in a nationally representative sample of US 
adults. We investigate the dose-response relationships of baseline serum Mg concentrations with 
risk of mortalities in a large, nationally representative sample of US adults. 
Methods: We analyzed prospective data of 14,353 participants aged 25-74 years with measures 
of serum Mg concentrations at baseline (1971-1975) from the National Health and Nutrition 
Examination Survey I Epidemiologic Follow-up Study (NHEFS). Mortality data was linked 
through December 31, 2011. We estimated the mortality hazard ratios (HRs), for participants 
within serum Mg categories of <0.7, 0.7-0.74, 0.75-0.79, 0.8-0.89 (referent), 0.9-0.94, 0.95-0.99, 
and ≥1.0mmol/L using weighted multivariate-adjusted Cox proportional hazards models.  
Results: During a median follow-up of 28.6 years, 9,012 deaths occurred, including 3,959 CVD 
deaths, 1,923 cancer deaths, and 708 stroke deaths. The multivariate-adjusted HRs (95% CIs) of 
all-cause mortality across increasing categories of Mg were 1.34 (1.02, 1.77), 0.94 (0.75, 1.18), 
1.08 (0.97, 1.19), 1.00 (referent), 1.05 (0.95, 1.16), 0.96 (0.79, 1.15), and 0.98 (0.76, 1.26). 
Similar trends were observed for cancer (HRs for serum Mg <0.7: 1.39, 95% CI: 0.83, 2.32) and 
CVD mortality (HRs for serum Mg <0.7: 1.28, 95% CI: 0.81, 2.02) but were not statistically 
significant. An elevated risk for stroke mortality was observed among participants with serum 
Mg < 0.70mmol/L (HR: 2.55, 95% CI: 1.18, 5.48).  
Conclusions: Very low serum Mg concentrations were significantly associated with an increased 
risk of all-cause mortality in US adults. 
Keywords: serum Mg, Mg deficiency, all-cause mortality, CVD mortality, cancer mortality, 
stroke mortality   
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INTRODUCTION 
As a cofactor in hundreds of enzymatic reactions in the human body 1, magnesium (Mg) 
plays a significant role in multiple biological systems. Low Mg level has been associated with 
increased risk of chronic diseases in prospective studies, including cardiovascular disease (CVD) 
2, 3, type 2 diabetes 4-8, metabolic related diseases 9, 10, and colorectal cancer 11.  Mechanistic 
evidence supports a role for magnesium in cardiovascular diseases, including on blood pressure 
12 , oxidative stress 13, endothelial function 14  and thrombosis 15, and arrhythmia 16. Additionally, 
Mg supplementation may improve glucose induced insulin response and insulin-mediated 
glucose disposal among nondiabetic participants 17, 18  
Although multiple lines of evidence support a role of Mg in major chronic diseases, few 
longitudinal studies have examined the relationship between serum Mg and mortality. One study, 
based on data from NHANES I Follow-up Study 1971-75, examined the effects of serum Mg on 
risk of CVD and all-cause mortality and observed an inverse association between serum Mg and 
mortality from all cause and CVD in participants followed up through 1992 19. Recently, the 
NHANES I mortality follow-up has been extended to include deaths events through a longer-
term follow-up period, providing more than double the number of mortality cases (n = 9012) to 
enable us to not only evaluate associations with all-cause mortality, but also cause-specific 
mortality, including cancer and stroke. We hypothesize that the population with low serum Mg 
levels have a high risk of mortality. 
METHODS 
Study design and population 
We used data from the NHANES I 1971-1975, a multistage national probability survey, 
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designed  to evaluate the health and nutritional status of US general population 20. Among the 
representative sample of 32,000 US civilians selected, 14,407 participants at NHANES I (aged 
25-74 years) with complete medical examinations were included in a longitudinal follow-up 
study, NHEFS, in 1982 21. The baseline information for NHEFS, including demographic and 
socioeconomic information and physical and laboratory examinations, was provided by 
NHANES I. After excluding 54 participants with missing measures of serum Mg, we finally 
included a total of 14,353 participants in the analysis. The design of the NHANES has been 
reviewed and approved by Institutional Review Board at the Centers for Disease Control and 
Prevention. All subjects provided written informed consent. 
Outcome measures 
The NHEFS cohort study included four waves of follow-up periods in 1982-1984, 1986, 
1987, and 1992. The follow-up data contained information on health-related outcomes. Vital 
status was assessed and confirmed by proxy interviews, medical records, and death certificate 
through the National Death Index. New record linkages of NHEFS participants to death records 
through December 31, 2011 were conducted by National Center for Health Statistics 22, 23. Our 
primary outcomes included all-cause, CVD, cancer, and stroke mortality. Causes of mortality 
were divided into four categories using the Tenth Version of the International Classification of 
Diseases (ICD-10): cancer (C00-97), CVD (I00-78), ischemic heart disease (CHD) (I58-63), and 
stroke (I60-69) deaths.  
Baseline Mg measurements 
Non-fasting blood samples were collected and frozen  and then sent to the Centers for 
Disease Control and Prevention for biochemical assays. Serum Mg concentrations were 
determined during the baseline survey by atomic absorption spectrophotometry using the method 
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of Hansen and Freier 24. Quality control samples were analyzed with every 20 specimens, and the 
repeat limits were below 1.40 and above 2.10 mEq/L 25, 26. We converted the unit of “mEq/L” for 
serum Mg concentrations into “mmol/L” for this study.  
Confounders 
Covariates were measured at baseline, including age, sex, race, body mass index (BMI) 
(kg/m2), education (≥ high school degree, or < high school degree), alcohol intake (> 2 times per 
week, or < 2 times per week), levels of recreational and non-recreational physical activity (self-
report of being very active, moderately active, or quite inactive), smoking (never, former 
current), sitting blood pressure (mmHg), history of diabetes (self-reported physician diagnosed 
diabetes, or use of hypoglycemic medication), history of hypertension (self-reported physician 
diagnosis, or taking antihypertensive drugs), history of CVD (self-reported physician diagnosed 
heart failure, heart attack, stroke, or possible heart or circulatory troubles), serum calcium and 
cholesterol levels, and intake of vitamin or mineral supplements (self-reported any vitamin or 
mineral supplementation within last 30 days before the interview).  
Statistical analysis 
We estimated the hazard ratios (HRs) and 95% confidence intervals (CIs) of mortality for 
categories of serum Mg comparing to the reference group (0.80-0.89 mmol/L) using Cox 
proportional hazards models. Weights accounting for the complex sampling design of the survey 
were applied in Cox proportional hazards model. Age, sex, race, BMI, education, cigarette 
smoking status, alcohol consumption, physical activity,  history of hypertension, history of 
diabetes, and use of vitamin and/or mineral supplements were included as covariates in the 
models.  
In order to explore the possible dose-response relationship between serum Mg levels and 
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all-cause and cause-specific mortality, we fitted restricted cubic spline regression models with 
four knots at 0.73, 0.82, 0.87, and 0.96 mmol/L.  
Finally, pre-specified subgroup analyses and sensitivity analyses were also performed to 
explore potential effect modifications or assess the robustness of the results. The subgroup 
variables included age (< 65 yr or ≥ 65 yr), sex (men or women), race (white, black, or other), 
BMI (< 25 kg/m2 or ≥ 25 kg/m2), recreational physical activity (very active, moderately active, 
or quite inactive), non-recreational physical activity (very active, moderately active, or quite 
inactive), diabetes (yes or no), hypertension (yes or no), CVD (yes or no), cigarette smoking 
status (current smoker or non-smoker), alcohol consumption (current drinker or non-drinker), 
and use vitamin and/or mineral supplements (user or non-user). We also conducted survey 
logistic regression models adjusted for the above mentioned covariates to identify the variable(s) 
that independently predicted low serum Mg (<0.70 mmol/L). Low serum Mg was defined as 
serum Mg < 0.75 mmol/L, according to the normal reference range for serum Mg (33); and a 
very low level of serum Mg was defined as serum Mg < 0.70, according to the clinical cut-off for 
hypomagnesemia. We performed the interaction analyses testing low serum Mg associations 
with all-cause mortality, CVD mortality, cancer mortality, and stroke mortality in different 
population characteristics and health status mentioned above. Sensitivity analyses were 
conducted among participants without prevalent diabetes, hypertension, or CVD at baseline or by 
further adjustment for dietary potassium and calcium levels, as well as serum calcium 
concentrations.  
All statistical analyses were conducted by using SUDAN and SAS software (version 9.4; 
SAS Institute). For all analyses, P < 0.05 for 2-tailed tests was considered statistically 
significant. 
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RESULTS  
Baseline Characteristics and Distribution of Serum Mg Concentrations 
In the 1971-1975 NHANES I data set, a total of 14,353 participants aged 25-74 years had 
measures of serum Mg. Serum Mg concentrations were relatively normally distributed among all 
participants (Figure 1A) with a mean of 0.85 (SE: 0.02) mmol/L. The mean serum Mg 
concentrations were 0.02 mmol/L higher in men than women and 0.02 mmol/L higher in whites 
than blacks (all P-values < 0.001) (Figure 1B & 1C). Nearly 4% of men and 7% of women had 
serum Mg less than 0.75 mmol/L; serum Mg levels were extremely low (< 0.70 mmol/L) among 
1% of men and 2% of women. Participants with low serum Mg generally tended to be older, 
overweight, less educated, smoke, consume alcohol, have high blood pressure, or had lower 
family income (TABLE 1). After adjusted for potential confounders, women, non-white 
participants, current smokers, vitamin/mineral supplement users, or participants with diabetes, 
hypertension, or low levels of total cholesterol were more likely to have low serum Mg, 
respectively (TABLE 2). 
All-cause mortality 
During a median 28.6 years of follow-up, a total of 9,012 deaths (63%) among 14,353 
participants occurred. Among the 9,012 deaths, 3,959 (42%) were due to CVD, 1,923 (23%) due 
to cancer, and 708 (7%) due to stroke. Of stroke deaths, 542 (72%) died from ischemic stroke, 
125 (21%) from cerebral stroke, and 41 (7%) from other stroke. The mean age at death was 75 
years and the mean baseline serum Mg levels before death was 0.85 mmol/L. Nearly 50% of all 
deaths occurred in women, 29% were hypertensive participants, 6% had diabetes mellitus, and 
14% had CVD.  
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 By category of increasing serum Mg < 0.7, 0.7-0.74, 0.75-0.79, 0.8-0.89, 0.9-0.94, 0.95-
0.99, ≥ 1.0 mmol/L, the corresponding all-cause mortality rates were 3343, 1955, 1959, 1999, 
2230, 2259, 2307 per 100,000 person-years, respectively. Compared to the reference group 
(serum Mg of 0.8-0.89 mmol/L), the multivariable-adjusted risk of all-cause mortality for each 
group in ascending order was 1.34 (95% CI: 1.02, 1.77), 0.94 (0.75, 1.18), 1.08 (0.97, 1.19), 1.05 
(0.95, 1.16), 0.96 (0.79, 1.15), and 0.98 (0.76, 1.26), respectively (TABLE 3). An L-shaped 
curve was shown between serum Mg and all-cause mortality after adjusting for potential 
confounders (FIGURE 2). We did not detect any significant association between serum Mg 
levels and mortality after serum Mg levels reached 0.70 mmol/L. 
Cause-specific mortality 
After adjustment of age, sex, and race, participants with serum Mg levels < 0.70 mmol/L 
had a 57% and 58% higher risk of CVD and CHD mortality comparing to those with serum Mg 
levels of 08-0.89 mmol/L. However, these associations were not statistically significant after 
further adjusting for history of diabetes and hypertension (TABLE 2). The results of multivariate 
analysis showed participants with extremely low levels of serum Mg < 0.70 mmol/L had a high 
risk of stroke mortality compared with the reference group (HR: 2.55; 95% CI: 1.18, 5.48). 
Among subtypes of stroke including cerebral stroke, ischemic stroke, and other stroke, only risk 
of ischemic stroke was significantly high among participants with serum Mg lower than 0.7 
mmol/L (HR, 3.6; 95% CI: 1.56, 8.33). There was a 23% elevation in risk of cancer mortality 
(HR: 1.23; 95% CI: 1.01, 1.50) among those with a slightly higher level of Mg (0.9-0.95 
mmol/L) than 0.8-0.89 mmol/L.  
Subgroup and sensitivity analysis 
We found that an inverse association between risks of all-cause and CVD mortality and 
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levels of Mg was significant only in men; HRs were 6.87 (95% CI: 2.18, 21.68) for all-cause 
mortality and 2.47 (95% CI: 1.31, 4.67) for CVD mortality, respectively (FIGURE 3). The 
significant associations with all-cause and cancer mortality were observed only in blacks with 
HR of 2.07 (95% CI: 1.45, 2.95) for all-cause mortality and HR of 2.99 (95% CI: 1.39, 6.43) for 
cancer mortality, but not in whites with HR of 1.16 (95% CI: 0.83 1.63; P-interaction = 0.02) for 
all-cause mortality and HR of 0.92 (95% CI: 0.37, 2.27; P-interaction = 0.08) for cancer 
mortality (FIGURE 4). Current smokers with low serum Mg levels had higher risks of all-cause 
mortality (HR: 1.94; 95% CI: 1.48, 2.54) than those nonsmokers (HR: 1.04; 95% CI: 0.71, 1.53; 
P-interaction = 0.01). No significant interactions were observed between Mg and the following 
covariates: age, BMI, physical activity level, alcohol consumption, CVD, hypertension, and 
diabetes. 
 To evaluate the robustness of the results, we included dietary potassium and calcium 
levels and serum calcium concentrations in the adjusted model and found no changes in the 
associations between low levels of Mg and all-cause, CVD, and cancer mortality. When 
participants with diabetes mellitus, hypertension, or CVD were excluded, the association 
between low levels of Mg and all-cause mortality became stronger (HR: 2.00; 95% CI: 1.34, 
2.97). However, further adjustment of dietary factors attenuated the significant association of 
low serum Mg with stroke mortality risk. Excluding patients with diabetes mellitus, 
hypertension, or CVD drove the association between high serum Mg and risk of cancer mortality 
towards the null. 
DISCUSSION 
In this large nationally representative sample of US adults with an average of 28 years of follow-
up, we observed that very low serum Mg concentrations (< 0.70 mmol/L) were significantly 
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associated with all-cause mortality. Although similar trends were observed for cancer and CVD 
mortality, they did not reach statistical significance. Additionally, there was suggestive evidence 
that serum Mg < 0.70 mmol/L was associated with increased risks of mortality due to total stroke 
or ischemic stroke. Our findings support the hypothesis that very low serum Mg may be 
clinically useful for predicting mortality and other long-term health outcomes in the general 
population. 
The serum Mg threshold we identified in US adults refines the associations between 
serum Mg concentrations and long-term health outcomes. Only few studies have evaluated the 
threshold of serum Mg to mortality or CVD risk. Several studies among patients receiving 
hemodialysis investigated the threshold effect of serum Mg levels on mortality and suggested a 
higher cut-off point of serum Mg (> 0.95 mmol/L) for predicting mortality 27-29. However, Mg 
homeostasis among kidney diseases patients differs from healthy individuals; therefore, these 
findings are of limited relevance to the general population. Moreover, previous NHANES studies 
examining the association of serum Mg and mortality used a reference value of < 0.8 mmol/L, 
potentially obscuring the association of elevated mortality risk only present at the lower 
concentrations (<0.7mmol/L) we observed in our study19.  
Several mechanisms may explain the beneficial effects of Mg, including maintaining 
glucose and insulin homeostasis 30, 31, improving lipid metabolism 32-35, enhancing the vascular or 
myocardial contractility 36-38 and vasodilation 36, 38-40, providing anti-arrhythmic 41, 42 and anti-
platelet effects 37, 39, 43, 44. Moreover, several small secondary prevention randomized trials have 
shown that oral Mg supplementation improved endothelial function 14, reduced thrombosis 15, 
increased cardiopulmonary function and left ventricular ejection fraction index 45 of CVD 
patients. Mg deficiency may increase the risk of various cardiac events and cardiac death 46-48. 
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Although we did not observe the Mg-cancer mortality association in this study, several evidence 
indicated that metabolic disorders induced by Mg deficiency might be risk factors of colorectal 
and pancreatic cancer 11. Previous animal studies and cell cultures suggest a role for Mg in 
carcinogenesis through its effects on cell proliferation, differentiation, apoptosis, and 
angiogenesis 49 as well as innate immunity and inflammation 50, 51. 
Previous observational studies have linked low Mg levels and chronic diseases 2-8, 11, 
which are major contributors to all-cause mortality and cause-specific mortality in the US. We 
found that there were decrease trends in both SBP/DBP levels and prevalence of diabetes and 
hypertension as serum Mg increased. And participants with hypertension or diabetes were more 
likely to be with Mg deficiency, the risk was twice higher than general population. To minimize 
residual confounding due to these diseases, we controlled for history of hypertension, diabetes 
mellitus, BMI, and vitamin/mineral supplements use in our multivariate model. Moreover, 
subgroup analyses stratifying by these factors were also conducted, but no significant 
interactions were detected. Although history of diabetes, CVD, and hypertension did not 
significantly modify the relation of serum Mg with mortality, the association was strengthened in 
the general population after excluding those with these diseases.  
In this study, we observed an association of low serum Mg levels with all-cause and CVD 
mortality in men only. Meanwhile, the average Mg levels in men were 0.02 mmol/L higher than 
that in women. And the prevalence of Mg < 0.70 mmol/L was 50% lower in men than in women 
in our study. Consistent with our findings, a pooled analysis of two large population-based 
cohort studies of Chinese adults showed that low circulating Mg levels were associated with to 
high risks of all-cause mortality and CHD mortality only in men 52. An elevated risk for 
mortality with low Mg was also found in a cohort of 4,035 men aged 30-60 years in France 53. 
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Similarly, inverse association between circulating Mg and ischemic heart disease was only 
reported among studies with more male participants (percentage of male ≥ median) in a meta-
analysis 2. As a mechanism for potential between-gender differences in the pathophysiology of 
low serum Mg on disease risk is unclear, this finding may be due to chance. In any case, these 
findings warrant further study. 
We also found that Mg deficiency was associated with a twice higher risk of all-cause 
mortality among smokers than non-smokers. These findings are consistent with risks from Mg 
deficiency among smokers reported in several epidemiological studies 54-56. Poor Mg status, 
together with long-term exposure to thiocyanate anions among smokers, accelerates the 
atherosclerotic processes in animal models 57. Moreover, a randomized clinical trial found that 
Mg deficiency accelerates the development of nicotine addiction through increasing the Mg 
dependent N-Methyl-D-aspartic acid or N-Methyl-D-aspartate receptors activity 58. Our findings, 
combined with these studies, suggest that a possible interplay between low serum Mg and 
smoking might amplify the effects of each risk factor alone on disease risk.   
Our study has several major strengths. Our use of NHANES data provided large 
nationally representative sample of the US adult population, increasing generalizability. The long 
follow-up and large number of cases (n > 9000) in our study increased statistical power. While 
dietary Mg has some limitations due to collinearity with dietary potassium, and recall bias 
introduced by using food frequency questionnaire, both of these limitations do not apply to 
serum Mg. Our examination of cause-specific mortality, and dose-response relationships using 
splines, represents the largest and most in-depth examination of the association of serum Mg and 
mortality yet conducted.  
Several limitations merit consideration. First, given the nature of the observational 
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studies, we cannot draw conclusions on causal relations between serum Mg and mortality. 
Second, the influence of possible change in Mg status on mortality risk cannot be assessed in the 
lack of longitudinal measurements of serum Mg. This gap needs to be addressed in future 
studies. Finally, the possibility of residual confounding due to unmeasured/ poorly measured 
factors or time-varying factors cannot be excluded. 
In conclusion, our results from a large, nationally representative, and prospective study 
indicated that baseline serum Mg at a low level of < 0.70 mmol/L was significantly associated 
with an increased risk of all-cause mortality in US adults over an average follow-up of 28 years. 
Our findings support the hypothesis that serum Mg may be clinically useful for predicting long-
term health outcomes and mortality in the general population. 
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FIGURES LEGENDS 
FIGURE 1: Weighted histogram of serum Mg levels in 14,353 participants (8,555 Women and 
5,798 men) at baseline (1971-1975) for total and by sex and race. 
FIGURE 2: Adjusted hazard ratios of all-cause mortality in the US general adults (NHANES I 
1971-2011). The solid curve represents for multivariate-adjusted hazard ratios calculated by 
restricted cubic splines with knots at serum Mg levels of 0.73, 0.82, 0.87, and 0.96 mmol/L. The 
reference value (HR = 1) was set at serum Mg levels of 0.80 mmol/L. Hazard ratios were 
estimated by using weighted Cox regression model adjusted for age, sex, race/ethnicity, 
education, family income, smoking status, alcohol consumptions, physical activity, BMI, history 
of diabetes, hypertension, and vitamin and/or mineral supplements use. 
FIGURE 3: Multivariate-adjusted hazard ratios (95% CIs) for all-cause, CVD, and cancer 
mortality by 7 categories of serum Mg level among women and men. 
FIGURE 4: Hazard ratios (95% CIs) of all-cause, CVD, and cancer mortality stratified by age, 
race, BMI, recreational physical activity, non-recreational physical activity, diabetes, 
hypertension, CVD, smoking status, alcohol consumption, and vitamin and/or mineral 
supplements use. Gray line indicates no increase in mortalities (HR = 1). Error bars indicate 95% 
CIs.  
* RPA indicates the recreational physical activity, and ** NRPA indicates non-recreational 
physical activity.  
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Table 1. Baseline characteristics by categories of serum Mg levels among population of NHANES I 1971- 1975 
Characteristics 
Serum Mg, mmol/L 
< 0.7 0.7-0.75 0.75-0.8 0.8-0.9 0.9-0.95 0.95-1.0 ≥ 1.0 P 
n=267 n=759 n=2,266 n=7,817 n=2,230 n=763 n=251 
Age, years 49.5 (1) 44.6 (0.6) 45.3 (0.4) 46 (0.2) 47.4 (0.4) 48 (0.6) 49.6 (1.1) < 0.0001 
Female, % 183 (66.9) 519 (65.6) 1504 (61.7) 4595 (51.6) 1189 (45) 421 (46.5) 144 (48) < 0.0001 
Ethnicity, %        < 0.0001 
       Black 113 (28) 240 (19.4) 479 (14.7) 1034 (8.6) 223 (6.8) 66 (7) 38 (9.2)  
       White 151 (72) 513 (80.6) 1770 (85.3) 6683 (91.4) 1981 (93.2) 694 (93) 211 (90.8)  
≥ High school degree, % 104 (47.4) 381 (62) 1267 (64.9) 4361 (63.5) 1206 (62.4) 430 (66.6) 130 (64.4) 0.003 
Smoking status, %        0.05 
Former smoker 34 (18.1) 84 (14.6) 341 (18.4) 1293 (20.3) 379 (19.7) 127 (20.8) 38 (18.8)  
Current smoker 95 (47.1) 272 (46.6) 753 (39.8) 2512 (40.1) 676 (38.7) 231 (36.9) 60 (32.8)  
Current drinker, % 158 (58.2) 379 (51.4) 1175 (51.1) 4131 (51.7) 1244 (56.5) 433 (54.5) 154 (65.2) 0.0003 
Family income /month, %        < 0.0001 
       ≤ $4,999 121 (38.3) 271 (23.4) 630 (19.8) 2016 (17.8) 591 (18.1) 213 (18) 86 (22.4)  
       $5,000- $10,000 71 (26) 204 (27.5) 659 (27.9) 2278 (28.5) 681 (30.1) 209 (26.8) 86 (34.2)  
       ≥ $10,000 75 (35.7) 284 (49.2) 977 (52.3) 3523 (53.6) 958 (51.9) 341 (55.1) 79 (43.4)  
Recreational physical activity, %       0.88 
       Low 67 (46.4) 219(49.1) 769 (50.6) 2705(51.1) 799 (49.8) 245 (47.1) 76 (51.9)  
       Moderate to high 23 (13.8) 84 (16.8) 248 (16.9) 873 (16.8) 236 (16.7) 97 (19.8) 27 (17.4)  
Non-recreational physical activity, %       0.04 
       Low 82 (48.9) 270 (55.8) 857 (54.7) 3082 (55.7) 868 (52) 312 (60.6) 98 (64.8)  
       Moderate to high 37 (26.3) 138 (27.8) 432 (29.1) 1507 (28.7) 438 (29.7) 154 (26.7) 33 (21.3)  
Body mass index, kg/m2 25.6 (0.6) 26.1 (0.3) 25.5 (0.2) 25.6 (0.1) 25.6 (0.1) 25.6 (0.2) 25.1 (0.3) < 0.0001 
SBP, mmHg 143.8 (3.0) 134.1 (1.34) 132 (1.1) 131.5 (0.6) 132.7 (1.0) 133 (1.4) 133.5 (2.4) < 0.0001 
DBP, mmHg 89.9 (2) 84.8 (0.8) 84.3 (0.6) 84.2 (0.3) 85.4 (0.6) 84.7 (0.9) 85.5 (1.4) < 0.0001 
Hypertension, % 116 (43.2) 233 (25.6) 568 (22.9) 1873 (21.2) 517 (19.8) 198 (23.4) 70 (23.8) < 0.0001 
Type 2 diabetes, % 42 (15.1) 59 (9.4) 133 (6.8) 361 (4.6) 85 (4.2) 28 (3.9) 17 (9.3) < 0.0001 
Serum         
     Calcium, mmol/L 9.7 (0.07) 9.6 (0.03) 9.6 (0.02) 9.7 (0.02) 9.7 (0.02) 9.7 (0.03) 9.8 (0.05) < 0.0001 
     Total cholesterol, mmol/L 5.6 (0.10) 5.5 (0.06) 5.6 (0.02) 5.7 (0.02) 5.9 (0.04) 5.9 (0.06) 5.8 (0.14) < 0.0001 
Dietary         
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     Total energy intake,       168 (8.1) 182.3 (6.3) 179.6 (2.7) 193 (2.1) 197 (3.3) 187.7 (6.4) 187 (13) < 0.0001 
     kcal/day 
     Vitamin/mineral    90 (36.1) 245 (35.3) 732 (32) 2611 (34.3) 775 (36.1) 261 (34.5) 87 (35.1) 0.47 
     Supplements use (Yes, %) 
P values are presented for linear trend test. 
The means (SEs) were calculated for continuous variables, and n (frequency) was presented for categorical variables.                      
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Table 2. Independent predictors of Mg deficiency (serum Mg < 0.7 mmol/L or 0.75 mmol/L) among 
14,353 adults older than 20 years 
Characters 
Mg deficiency 
Mg < 0.70 mmol/L Mg < 0.75 mmol/L 
OR (95% CI) P-value OR (95% CI) P-value 
Age, per 10 yr 1.04 (0.88, 1.23) 0.65 0.92 (0.83, 1.02) 0.11 
Female sex 2.22 (1.19, 4.13) 0.01 1.89 (1.43, 2.50) < 0.0001 
Race/ethnicity, non-white race 3.12 (1.93, 5.05) < 0.0001 2.53 (1.98, 3.23) < 0.0001 
≥ High school degree 1.45 (0.84, 2.49) 0.19 1.06 (0.82, 1.36) 0.68 
Family income, per $5,000/month 0.86 (0.59, 1.27) 0.45 0.90 (0.76, 1.06) 0.20 
BMI, ≥ 25 vs < 25 kg/m2 0.69 (0.40, 1.18) 0.17 0.99 (0.76, 1.28) 0.91 
Recreational physical activity     
    Low 1.22 (0.74, 2.03) 0.27 1.04 (0.81, 1.34) 0.74 
    Moderate to high 0.85 (0.39, 1.86) 0.47 1.00 (0.74, 1.37) 0.90 
Smoking, vs never smoker     
    Current smoker 1.69 (0.98, 2.94) 0.64 1.59 (1.19, 2.13) 0.02 
    Former smoker 2.23 (1.02, 4.90) 0.14 1.39 (0.96, 2.01) 0.56 
Current drinker 1.22 (0.79, 1.90) 0.37 1.15 (0.92, 1.45) 0.23 
Supplement use, Yes 1.56 (1.02, 2.41) 0.04 1.17 (0.93, 1.46) 0.19 
Diabetes, Yes 2.82 (1.39, 5.73) 0.004 2.74 (1.61, 4.68) 0.0002 
CVD, Yes 0.88 (0.38, 2.03) 0.76 1.07 (0.68, 1.68) 0.77 
Hypertension, Yes 2.18 (1.31, 3.63) 0.003 1.38 (1.00, 1.90) 0.05 
Total cholesterol, per mg/dL 0.79 (0.63, 0.98) 0.04 0.84 (0.75, 0.93) 0.001 
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Table 3. Mortality rates and adjusted hazard ratios (95% CIs) of all-cause, cancer, CVDs, CHD, and 
stroke across the categories of baseline serum Mg concentrations. 
Serum Mg, 
mmol/L 
No. of events/ 
all participants Mortality 
a Hazard ratio (95% CI) b 
Hazard ratio 
(95% CI) c 
Hazard ratio 
(95% CI) d 
All-cause mortality 
< 0.7 211/ 267 3343 1.69 (1.33, 2.14) 1.73 (1.34, 2.22) 1.34 (1.02, 1.77)* 
0.7 - 0.75 470/ 759 1955 1.21 (1.04, 1.41) 0.98 (0.80, 1.21) 0.94 (0.75, 1.18) 
0.75 - 0.8 1309/ 2266 1959 1.14 (1.06, 1.23) 1.05 (0.96, 1.16) 1.08 (0.97, 1.19) 
0.8 - 0.9 4828/ 7817 1999 1 1 1 
0.9 - 0.95 1499/ 2230 2230 1.01 (0.94, 1.08) 1.00 (0.91, 1.09) 1.05 (0.95, 1.16) 
0.95 - 1.0 523/ 763 2259 0.95 (0.85, 1.08) 0.95 (0.83, 1.09) 0.96 (0.79, 1.15) 
≥ 1.0 172/ 251 2307 1.01 (0.84, 1.21) 0.92 (0.74, 1.16) 0.98 (0.76, 1.26) 
Cancer mortality 
< 0.7 36/ 267 592 1.36 (0.93, 1.97) 1.39 (0.92, 2.11) 1.39 (0.83, 2.32) 
0.7 - 0.75 80/ 759 390 1.01 (0.73, 1.39) 0.88 (0.59, 1.32) 0.90 (0.57, 1.44) 
0.75 - 0.8 306/ 2266 452 1.11 (0.94, 1.31) 1.09 (0.90, 1.32) 1.12 (0.89, 1.42) 
0.8 - 0.9 1055/ 7817 464 1 1 1 
0.9 - 0.95 314/ 2230 529 1.05 (0.90, 1.24) 1.03 (0.86, 1.25) 1.23 (1.01, 1.50)* 
0.95 - 1.0 104/ 763 480 0.91 (0.69, 1.20) 0.92 (0.69, 1.24) 0.98 (0.71, 1.35) 
≥ 1.0 28/ 251 411 0.80 (0.50, 1.28) 0.49 (0.24, 0.96) 0.57 (0.27, 1.22) 
CVD mortality 
< 0.7 88/ 267 1343 1.57 (1.10, 2.22) 1.55 (1.02, 2.34) 1.28 (0.81, 2.02) 
0.7 - 0.75 217/ 759 855 1.29 (1.02, 1.63) 1.03 (0.76, 1.41) 0.98 (0.70, 1.37) 
0.75 - 0.8 563/ 2266 835 1.18 (1.04, 1.33) 1.09 (0.93, 1.28) 1.15 (0.95, 1.39) 
0.8 - 0.9 2076/ 7817 832 1 1 1 
0.9 - 0.95 690/ 2230 978 1.04 (0.92, 1.17) 1.02 (0.88, 1.18) 1.03 (0.86, 1.23) 
0.95 - 1.0 241/ 763 979 0.97 (0.81, 1.15) 1.00 (0.81, 1.25) 1.08 (0.81, 1.44) 
≥ 1.0 84/ 251 1124 1.16 (0.89, 1.50) 1.25 (0.91, 1.72) 1.45 (1.07, 1.96) 
CHD mortality 
< 0.7 53/ 267 758 1.58 (1.04, 2.41) 1.49 (0.91, 2.43) 1.15 (0.64, 2.04) 
0.7 - 0.75 124/ 759 507 1.35 (1.00, 1.83) 0.95 (0.64, 1.42) 0.85 (0.55, 1.34) 
0.75 - 0.8 324/ 2266 519 1.27 (1.07, 1.51) 1.10 (0.90, 1.35) 1.20 (0.94, 1.53) 
0.8 - 0.9 1179/ 7817 485 1 1 1 
0.9 - 0.95 412/ 2230 589 1.06 (0.91, 1.23) 1.02 (0.84, 1.23) 1.02 (0.80, 1.30) 
0.95 - 1.0 143/ 763 598 1.01 (0.81, 1.25) 1.03 (0.79, 1.34) 1.11 (0.78, 1.59) 
≥ 1.0 48/ 251 598 1.07 (0.73, 1.57) 1.06 (0.65, 1.72) 1.29 (0.77, 2.17) 
Stroke mortality 
< 0.7 16/ 267 287 1.81 (0.92, 3.57) 2.67 (1.31, 5.45) 2.55 (1.18, 5.48)* 
0.7 - 0.75 38/ 759 106 0.92 (0.58, 1.47) 0.92 (0.51, 1.68) 0.86 (0.47, 1.59) 
0.75 - 0.8 99/ 2266 121 0.97 (0.73, 1.29) 1.02 (0.70, 1.48) 1.01 (0.65, 1.56) 
0.8 - 0.9 379/ 7817 144 1 1 1 
0.9 - 0.95 107/ 2230 150 0.91 (0.67, 1.24) 0.93 (0.65, 1.33) 0.92 (0.60, 1.42) 
0.95 - 1.0 52/ 763 222 1.27 (0.86, 1.87) 1.41 (0.87, 2.28) 1.46 (0.85, 2.52) 
≥ 1.0 17/ 251 250 1.44 (0.79, 2.61) 1.58 (0.76, 3.26) 1.72 (0.88, 3.38) 
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a: The mortalities were calculated as per 100,000 person-years. 
b: The HRs (95% CIs) were calculated based on the model 1: adjusted for age, gender and race; 
c: The HRs (95% CIs) were calculated based on the model 2: adjusted for age, gender, race, BMI, 
physical activity, smoking status, and alcohol consumption;  
d: The HRs (95% CIs) were calculated based on the model 3: adjusted for age, gender, race, BMI, 
physical activity, education, smoking status, alcohol consumption, history of diabetes, history of 
hypertension, and vitamin or mineral supplements use. 
Figure 1. 
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